MeSH tree: C23.550.727
Low-grade brain tumors known as IDH-mutant gliomas CNS WHO grade 2 are life-threatening in spite of their slow growth. Neurosurgeons across the globe are faced with the question as to striking the correct balance between ...
Jan 19, 2026
0
22
Stanford University-led researchers report that tumor cells hijack mitochondria from immune cells, reducing anti-tumor immune function and activating cGAS-STING and type I interferon signaling that promotes lymph node metastasis.
Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies. TNBC is also more likely to metastasize, or travel through the bloodstream to spread to other organs, ...
Jan 15, 2026
0
11
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting ...
Jan 14, 2026
0
11
A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has developed and validated an artificial intelligence (AI)–based noninvasive tool that can predict the likelihood that a patient's oropharyngeal ...
Dec 24, 2025
0
19
A UK research team has developed a pioneering blood test that could change the way lung cancer is detected and monitored.
Dec 16, 2025
0
14
Pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat due to its aggressive nature and limited prognostic tools. While the traditional staging systems, such as the TNM classification, focus on anatomical ...
Dec 13, 2025
0
13
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive ...
Dec 9, 2025
0
17
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive ...
Dec 9, 2025
0
12
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.
Dec 8, 2025
0
14
